• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Identification of Risk Factors for Initial Elevated Vancomyin Trough Concentrations.初始万古霉素谷浓度升高的危险因素识别。
J Pharm Technol. 2016 Feb;32(1):29-33. doi: 10.1177/8755122515599553. Epub 2015 Aug 12.
2
Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function.肾功能正常的儿科重症监护病房患者的万古霉素剂量需求
J Crit Care. 2000 Mar;15(1):1-4. doi: 10.1053/jcrc.2000.0150001.
3
Assessment of initial serum vancomycin trough concentrations and their association with initial empirical weight-based vancomycin dosing and development of nephrotoxicity in children: a multicenter retrospective study.儿童初始血清万古霉素谷浓度评估及其与基于体重的初始经验性万古霉素给药和肾毒性发生的关联:一项多中心回顾性研究。
Pharmacotherapy. 2015 Mar;35(3):337-43. doi: 10.1002/phar.1552. Epub 2015 Mar 10.
4
Identification of risk factors for nephrotoxicity in patients receiving extended-duration, high-trough vancomycin therapy.接受延长疗程、高谷浓度万古霉素治疗患者肾毒性危险因素的识别。
Can J Hosp Pharm. 2014 Mar;67(2):126-32. doi: 10.4212/cjhp.v67i2.1340.
5
Utilization of Augmented Renal Clearance in Trauma Intensive Care Scoring System to Improve Vancomycin Dosing in Trauma Patients at Risk for Augmented Renal Clearance.在创伤重症监护评分系统中利用增强肾清除率来改善有增强肾清除率风险的创伤患者的万古霉素给药剂量。
Surg Infect (Larchmt). 2020 Feb;21(1):43-47. doi: 10.1089/sur.2019.026. Epub 2019 Jul 23.
6
Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project.胱抑素 C 指导下的危重症患者万古霉素剂量调整:一项质量改进项目。
Am J Kidney Dis. 2017 May;69(5):658-666. doi: 10.1053/j.ajkd.2016.11.016. Epub 2017 Jan 25.
7
[Predictive performance of population pharmacokinetic software on vancomycin steady-state trough concentration].[群体药代动力学软件对万古霉素稳态谷浓度的预测性能]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Jan;32(1):50-55. doi: 10.3760/cma.j.cn121430-20190814-00009.
8
[Clinical verification of vancomycin population pharmacokinetics in patients with augmented renal clearance].万古霉素群体药代动力学在肾脏清除率增加患者中的临床验证
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018 May;30(5):444-448. doi: 10.3760/cma.j.issn.2095-4352.2018.05.010.
9
Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center.从基于万古霉素谷浓度的给药方案转换为基于曲线下面积的给药方案:在成人中使用两次样本测量的实施。
Pharmacotherapy. 2019 Apr;39(4):433-442. doi: 10.1002/phar.2234. Epub 2019 Mar 18.
10
The Relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis.老年人群中万古霉素谷浓度与肾毒性的关系:回顾性分析。
Ann Pharmacother. 2012 Nov;46(11):1477-83. doi: 10.1345/aph.1R158. Epub 2012 Oct 16.

引用本文的文献

1
Antimicrobial resistance (AMR) nanomachines-mechanisms for fluoroquinolone and glycopeptide recognition, efflux and/or deactivation.抗菌耐药性(AMR)纳米机器——氟喹诺酮和糖肽的识别、外排和/或失活机制
Biophys Rev. 2018 Apr;10(2):347-362. doi: 10.1007/s12551-018-0404-9. Epub 2018 Mar 10.
2
Full hydrodynamic reversibility of the weak dimerization of vancomycin and elucidation of its interaction with VanS monomers at clinical concentration.万古霉素弱二聚化的完全流体动力学可逆性及其与临床浓度下 VanS 单体相互作用的阐明。
Sci Rep. 2017 Oct 5;7(1):12697. doi: 10.1038/s41598-017-12620-z.

本文引用的文献

1
Individualized vancomycin dosing in obese patients: a two-sample measurement approach improves target attainment.肥胖患者的个体化万古霉素给药:双样本测量方法可提高目标达成率。
Pharmacotherapy. 2015 May;35(5):455-63. doi: 10.1002/phar.1588.
2
The association of elevated trough serum vancomycin concentrations with obesity.血清万古霉素谷浓度升高与肥胖的关联。
J Infect Chemother. 2015 Jul;21(7):507-11. doi: 10.1016/j.jiac.2015.03.007. Epub 2015 Mar 20.
3
Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.万古霉素在疑似或确诊金黄色葡萄球菌感染的极度肥胖患者中的药代动力学。
Pharmacotherapy. 2015 Feb;35(2):127-39. doi: 10.1002/phar.1531. Epub 2015 Feb 3.
4
Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review.医院基于体重的抗菌药物给药指南对病态肥胖成年人的影响及综合文献综述
J Clin Pharm Ther. 2014 Dec;39(6):584-608. doi: 10.1111/jcpt.12200. Epub 2014 Sep 9.
5
Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors.成年内科患者中万古霉素相关肾毒性:发生率、转归及危险因素
Pharmacotherapy. 2014 Jul;34(7):653-61. doi: 10.1002/phar.1423. Epub 2014 Apr 3.
6
Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter.系统评价和荟萃分析万古霉素诱导的肾毒性与维持谷浓度在 15 至 20 毫克/升之间的给药方案相关。
Antimicrob Agents Chemother. 2013 Feb;57(2):734-44. doi: 10.1128/AAC.01568-12. Epub 2012 Nov 19.
7
Decreased vancomycin clearance in patients with congestive heart failure.充血性心力衰竭患者的万古霉素清除率降低。
Eur J Clin Pharmacol. 2013 Mar;69(3):449-57. doi: 10.1007/s00228-012-1340-4. Epub 2012 Jul 12.
8
Performance of a vancomycin dosage regimen developed for obese patients.肥胖患者用万古霉素剂量方案的疗效。
Am J Health Syst Pharm. 2012 Jun 1;69(11):944-50. doi: 10.2146/ajhp110324.
9
Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review.万古霉素相关性肾毒性:机制、发生率、危险因素及特殊人群。文献综述。
Eur J Clin Pharmacol. 2012 Sep;68(9):1243-55. doi: 10.1007/s00228-012-1259-9. Epub 2012 Mar 13.
10
Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population.成人急性髓系白血病患者群体中万古霉素药代动力学特征
J Oncol Pharm Pract. 2012 Mar;18(1):91-6. doi: 10.1177/1078155211402107. Epub 2011 Apr 26.

初始万古霉素谷浓度升高的危险因素识别。

Identification of Risk Factors for Initial Elevated Vancomyin Trough Concentrations.

作者信息

MacDougall Julie, Ahern John, Civalier Maria, Pierce Kristin, Cohen Roseanne

机构信息

University of Vermont Medical Center, Burlington, VT, USA.

出版信息

J Pharm Technol. 2016 Feb;32(1):29-33. doi: 10.1177/8755122515599553. Epub 2015 Aug 12.

DOI:10.1177/8755122515599553
PMID:34860965
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5998412/
Abstract

Recent literature suggests that elevated vancomycin trough concentrations (>20 µg/mL) may be associated with an increased risk of nephrotoxicity and lead to an increase in mortality and hospital length of stay. The purpose of this study was to identify variables that may be predictive of elevated initial vancomycin trough concentrations. Retrospective case-control study of all adult patients who had an initial vancomycin trough concentration measured between January 1, 2013, and December 31, 2014. Case patients had an initial trough concentration >20 µg/mL, while control patients had an initial trough concentration of ≤20 µg/mL. Patients were excluded from the study if they were in the intensive care unit, had unstable renal function, or if they had cystic fibrosis, solid organ transplant, or bone marrow transplant. Of the 512 vancomycin trough concentrations reviewed, 54 patients met the case definition, while 140 patients were randomly selected as controls. In a multivariate model, baseline serum creatinine, body mass index, heart failure, and malignancy were all independently predictive of an initial vancomycin concentration >20 µg/mL. Reduced baseline renal function coupled with increasing body mass index is associated with an increased risk of an elevated initial vancomycin trough concentration. This risk is further enhanced by the presence of heart failure and/or malignancy. When these risk factors are present, it may be prudent to consider implementation of individualized dosing to achieve initial target concentrations.

摘要

近期文献表明,万古霉素谷浓度升高(>20µg/mL)可能与肾毒性风险增加相关,并导致死亡率上升和住院时间延长。本研究的目的是确定可能预测初始万古霉素谷浓度升高的变量。对2013年1月1日至2014年12月31日期间首次测量万古霉素谷浓度的所有成年患者进行回顾性病例对照研究。病例组患者的初始谷浓度>20µg/mL,而对照组患者的初始谷浓度≤20µg/mL。如果患者在重症监护病房、肾功能不稳定,或者患有囊性纤维化、实体器官移植或骨髓移植,则被排除在研究之外。在审查的512次万古霉素谷浓度中,54例患者符合病例定义,同时随机选择140例患者作为对照。在多变量模型中,基线血清肌酐、体重指数、心力衰竭和恶性肿瘤均独立预测初始万古霉素浓度>20µg/mL。基线肾功能降低加上体重指数增加与初始万古霉素谷浓度升高的风险增加相关。心力衰竭和/或恶性肿瘤的存在会进一步增加这种风险。当存在这些风险因素时,考虑实施个体化给药以达到初始目标浓度可能是谨慎的做法。